2023 Q3 Form 10-Q Financial Statement
#000149315223028452 Filed on August 14, 2023
Income Statement
Concept | 2023 Q3 | 2023 Q2 | 2022 Q2 |
---|
Balance Sheet
Concept | 2023 Q3 | 2023 Q2 | 2022 Q2 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $5.720M | $8.521M | $15.76M |
YoY Change | -56.97% | -45.92% | -40.27% |
Cash & Equivalents | $5.700M | $8.500M | $15.76M |
Short-Term Investments | |||
Other Short-Term Assets | $510.0K | $737.0K | $1.317M |
YoY Change | -49.9% | -44.04% | 53.32% |
Inventory | $781.0K | $823.0K | $1.038M |
Prepaid Expenses | |||
Receivables | $102.0K | $106.0K | $81.00K |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $6.742M | $9.810M | $18.19M |
YoY Change | -56.47% | -46.08% | -35.06% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.101M | $1.209M | $1.329M |
YoY Change | -21.08% | -9.03% | -38.56% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $13.00K | $13.00K | $13.00K |
YoY Change | 0.0% | 0.0% | 0.0% |
Total Long-Term Assets | $1.749M | $1.931M | $1.889M |
YoY Change | -6.92% | 2.22% | -13.19% |
TOTAL ASSETS | |||
Total Short-Term Assets | $6.742M | $9.810M | $18.19M |
Total Long-Term Assets | $1.749M | $1.931M | $1.889M |
Total Assets | $8.491M | $11.74M | $20.08M |
YoY Change | -51.11% | -41.53% | -33.49% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.470M | $1.470M | $2.212M |
YoY Change | -45.47% | -33.54% | 2.88% |
Accrued Expenses | $220.0K | $243.0K | $266.0K |
YoY Change | -11.29% | -8.65% | 1.92% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $2.781M | $2.694M | $1.757M |
YoY Change | 13.37% | 53.33% | -77.99% |
Total Short-Term Liabilities | $4.529M | $4.451M | $4.253M |
YoY Change | -17.16% | 4.66% | -59.11% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $2.470M | $3.198M | $5.892M |
YoY Change | -52.96% | -45.72% | |
Other Long-Term Liabilities | $30.00K | $1.135M | $2.103M |
YoY Change | -98.51% | -46.03% | -4.45% |
Total Long-Term Liabilities | $2.470M | $3.198M | $5.892M |
YoY Change | -52.96% | -45.72% | 167.7% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $4.529M | $4.451M | $4.253M |
Total Long-Term Liabilities | $2.470M | $3.198M | $5.892M |
Total Liabilities | $10.97M | $12.70M | $16.11M |
YoY Change | -33.94% | -21.14% | 27.84% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$151.4M | -$148.7M | -$132.7M |
YoY Change | 9.97% | 12.05% | |
Common Stock | $0.00 | $1.000K | $0.00 |
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$2.478M | -$963.0K | $3.972M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $8.491M | $11.74M | $20.08M |
YoY Change | -51.11% | -41.53% | -33.49% |
Cashflow Statement
Concept | 2023 Q3 | 2023 Q2 | 2022 Q2 |
---|
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001686850 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
CY2023Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
usd | |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
usd | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
usd | |
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
usd | ||
MOTS |
Issuance Of Common Stock For Board Of Directors Compensation
IssuanceOfCommonStockForBoardOfDirectorsCompensation
|
usd | ||
MOTS |
Gross Proceeds From Private Placement Offering
GrossProceedsFromPrivatePlacementOffering
|
usd | ||
us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
usd | ||
MOTS |
Common Stock Issued To Settle Accrued Expenses For Board Of Directors Compensation
CommonStockIssuedToSettleAccruedExpensesForBoardOfDirectorsCompensation
|
usd | ||
MOTS |
Common Stock Issued To Settle Accrued Expenses For Board Of Directors Compensation
CommonStockIssuedToSettleAccruedExpensesForBoardOfDirectorsCompensation
|
usd | ||
MOTS |
Common Stock Issued For Prepaid Board Of Directors Compensation
CommonStockIssuedForPrepaidBoardOfDirectorsCompensation
|
usd | ||
MOTS |
Purchase Of Fixed Assets In Prepaid Expenses
PurchaseOfFixedAssetsInPrepaidExpenses
|
usd | ||
MOTS |
Noncash Issuance Costs From Private Placement
NoncashIssuanceCostsFromPrivatePlacement
|
usd | ||
MOTS |
Prepaid Expenses Resulting From Rightofuse Asset Obtained
PrepaidExpensesResultingFromRightofuseAssetObtained
|
usd | ||
CY2022Q4 | MOTS |
Restructuring Liabilities
RestructuringLiabilities
|
usd | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-06-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-38389 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Motus GI Holdings, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
81-4042793 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1301 East Broward Boulevard | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
3rd Floor | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Ft. Lauderdale | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
FL | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
33301 | ||
dei |
City Area Code
CityAreaCode
|
(954) | ||
dei |
Local Phone Number
LocalPhoneNumber
|
541 8000 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.0001 par value per share | ||
dei |
Trading Symbol
TradingSymbol
|
MOTS | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2023Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
5893453 | shares |
CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8521000 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14042000 | usd |
CY2023Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
106000 | usd |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
59000 | usd |
CY2023Q2 | MOTS |
Inventory Current
InventoryCurrent
|
446000 | usd |
CY2022Q4 | MOTS |
Inventory Current
InventoryCurrent
|
488000 | usd |
CY2023Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
737000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
781000 | usd |
CY2023Q2 | us-gaap |
Assets Current
AssetsCurrent
|
9810000 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
15370000 | usd |
CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1209000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1325000 | usd |
CY2023Q2 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
377000 | usd |
CY2022Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
511000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
332000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
428000 | usd |
CY2023Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
13000 | usd |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
13000 | usd |
CY2023Q2 | us-gaap |
Assets
Assets
|
11741000 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
17647000 | usd |
CY2023Q2 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
151000 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
182000 | usd |
CY2023Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
2694000 | usd |
CY2022Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
2532000 | usd |
CY2023Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1470000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1969000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
243000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
245000 | usd |
CY2023Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
44000 | usd |
CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
53000 | usd |
CY2023Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4451000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4799000 | usd |
CY2023Q2 | MOTS |
Convertible Debt Unamortized Discount Noncurrent
ConvertibleDebtUnamortizedDiscountNoncurrent
|
80000 | usd |
CY2022Q4 | MOTS |
Convertible Debt Unamortized Discount Noncurrent
ConvertibleDebtUnamortizedDiscountNoncurrent
|
108000 | usd |
CY2023Q2 | MOTS |
Convertible Note Noncurrent
ConvertibleNoteNoncurrent
|
3920000 | usd |
us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
6167271 | shares | |
CY2022Q4 | MOTS |
Convertible Note Noncurrent
ConvertibleNoteNoncurrent
|
3892000 | usd |
CY2023Q2 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
70000 | usd |
CY2022Q4 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
135000 | usd |
CY2023Q2 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
3198000 | usd |
CY2022Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
4589000 | usd |
CY2023Q2 | MOTS |
Contingent Royalty Obligation
ContingentRoyaltyObligation
|
1056000 | usd |
CY2022Q4 | MOTS |
Contingent Royalty Obligation
ContingentRoyaltyObligation
|
1212000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
79000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
178000 | usd |
CY2023Q2 | us-gaap |
Liabilities
Liabilities
|
12704000 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
14670000 | usd |
CY2023Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
115000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
115000000 | shares |
CY2023Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
5305441 | shares |
CY2023Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
5305441 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
4659769 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
4659769 | shares |
CY2023Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | usd |
CY2023Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
147770000 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
144328000 | usd |
CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-148734000 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-141351000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-963000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2977000 | usd |
CY2023Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
11741000 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
17647000 | usd |
CY2023Q2 | us-gaap |
Revenues
Revenues
|
113000 | usd |
CY2022Q2 | us-gaap |
Revenues
Revenues
|
185000 | usd |
us-gaap |
Revenues
Revenues
|
169000 | usd | |
us-gaap |
Revenues
Revenues
|
205000 | usd | |
CY2023Q2 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
31000 | usd |
CY2022Q2 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
68000 | usd |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
40000 | usd | |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
83000 | usd | |
CY2023Q2 | MOTS |
Costs Of Revenue Impairment Of Inventory
CostsOfRevenueImpairmentOfInventory
|
30000 | usd |
MOTS |
Costs Of Revenue Impairment Of Inventory
CostsOfRevenueImpairmentOfInventory
|
195000 | usd | |
MOTS |
Costs Of Revenue Impairment Of Inventory
CostsOfRevenueImpairmentOfInventory
|
159000 | usd | |
CY2023Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
759000 | usd |
CY2022Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1413000 | usd |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2213000 | usd | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2688000 | usd | |
CY2023Q2 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
337000 | usd |
CY2022Q2 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1222000 | usd |
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1179000 | usd | |
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2205000 | usd | |
CY2023Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1638000 | usd |
CY2022Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2075000 | usd |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3583000 | usd | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4189000 | usd | |
CY2023Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
2795000 | usd |
CY2022Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
4778000 | usd |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
7210000 | usd | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
9324000 | usd | |
CY2023Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2682000 | usd |
CY2022Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4593000 | usd |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7041000 | usd | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9119000 | usd | |
CY2023Q2 | MOTS |
Loss On Changes In Fair Value Of Contingent Royalty Obligation
LossOnChangesInFairValueOfContingentRoyaltyObligation
|
64000 | usd |
CY2022Q2 | MOTS |
Loss On Changes In Fair Value Of Contingent Royalty Obligation
LossOnChangesInFairValueOfContingentRoyaltyObligation
|
92000 | usd |
MOTS |
Loss On Changes In Fair Value Of Contingent Royalty Obligation
LossOnChangesInFairValueOfContingentRoyaltyObligation
|
-156000 | usd | |
MOTS |
Loss On Changes In Fair Value Of Contingent Royalty Obligation
LossOnChangesInFairValueOfContingentRoyaltyObligation
|
63000 | usd | |
CY2023Q2 | MOTS |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
246000 | usd |
CY2022Q2 | MOTS |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
359000 | usd |
MOTS |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
485000 | usd | |
MOTS |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
691000 | usd | |
CY2023Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-5000 | usd |
CY2022Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-96000 | usd |
us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-13000 | usd | |
us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-78000 | usd | |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2997000 | usd |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5140000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7383000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-9951000 | usd | |
CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.40 | |
CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.40 | |
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.86 | |
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.86 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.20 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.20 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.72 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.72 | ||
CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.40 | |
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.86 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.20 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.72 | ||
CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
7555903 | shares |
CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7555903 | shares |
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
2758457 | shares |
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2758457 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6167271 | shares | |
us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
2674536 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2674536 | shares | |
CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
7555903 | shares |
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
2758457 | shares |
us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
6167271 | shares | |
us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
2674536 | shares | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2977000 | usd |
CY2023Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
19000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
102000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
222000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4386000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-1085000 | usd |
CY2023Q2 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
731000 | usd |
CY2023Q2 | MOTS |
Stock Issued During Period Value Private Placement Offering Net Of Financing Fees
StockIssuedDuringPeriodValuePrivatePlacementOfferingNetOfFinancingFees
|
3070000 | usd |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
49000 | usd |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2997000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-963000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9657000 | usd |
CY2022Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
111000 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
3004000 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
235000 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
521000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4811000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8606000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8606000 | usd |
CY2022Q2 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
5000 | usd |
CY2022Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
45000 | usd |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
461000 | usd |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5140000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3972000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3972000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7383000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-9951000 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
230000 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
253000 | usd | |
us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
123000 | usd | |
us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
125000 | usd | |
MOTS |
Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation
GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation
|
156000 | usd | |
MOTS |
Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation
GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation
|
-63000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
271000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
982000 | usd | |
MOTS |
Impairment Of Inventory
ImpairmentOfInventory
|
195000 | usd | |
MOTS |
Impairment Of Inventory
ImpairmentOfInventory
|
159000 | usd | |
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
36000 | usd | |
MOTS |
Issuance Of Common Stock For Board Of Directors Compensation
IssuanceOfCommonStockForBoardOfDirectorsCompensation
|
118000 | usd | |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
121000 | usd | |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
175000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
47000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-28000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
33000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
764000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-44000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
407000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-604000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-459000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-125000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-177000 | usd | |
us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-9000 | usd | |
us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
8000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7373000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9811000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
88000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
49000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-88000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-49000 | usd | |
MOTS |
Gross Proceeds From Private Placement Offering
GrossProceedsFromPrivatePlacementOffering
|
3537000 | usd | |
us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
1325000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
121000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3165000 | usd | |
MOTS |
Equity Financing Fees
EquityFinancingFees
|
-393000 | usd | |
MOTS |
Equity Financing Fees
EquityFinancingFees
|
-111000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1940000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3054000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-5521000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-6806000 | usd | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
14042000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
22563000 | usd |
CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
8521000 | usd |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
15757000 | usd |
us-gaap |
Interest Paid Net
InterestPaidNet
|
476000 | usd | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
511000 | usd | |
MOTS |
Common Stock Issued For Prepaid Board Of Directors Compensation
CommonStockIssuedForPrepaidBoardOfDirectorsCompensation
|
117000 | usd | |
MOTS |
Purchase Of Fixed Assets In Prepaid Expenses
PurchaseOfFixedAssetsInPrepaidExpenses
|
4000 | usd | |
us-gaap |
Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
|
14000 | usd | |
us-gaap |
Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
|
62000 | usd | |
MOTS |
Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses
PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
|
12000 | usd | |
MOTS |
Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses
PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
|
75000 | usd | |
MOTS |
Financing Fees Included In Accounts Payable And Accrued Expenses
FinancingFeesIncludedInAccountsPayableAndAccruedExpenses
|
93000 | usd | |
MOTS |
Financing Fees Included In Accounts Payable And Accrued Expenses
FinancingFeesIncludedInAccountsPayableAndAccruedExpenses
|
5000 | usd | |
MOTS |
Noncash Issuance Costs From Private Placement
NoncashIssuanceCostsFromPrivatePlacement
|
264000 | usd | |
MOTS |
Rightofuse Asset Obtained In Exchange For Lease Obligation
RightofuseAssetObtainedInExchangeForLeaseObligation
|
35000 | usd | |
MOTS |
Rightofuse Asset Obtained In Exchange For Lease Obligation
RightofuseAssetObtainedInExchangeForLeaseObligation
|
34000 | usd | |
MOTS |
Prepaid Expenses Resulting From Rightofuse Asset Obtained
PrepaidExpensesResultingFromRightofuseAssetObtained
|
3000 | usd | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="xdx_80A_eus-gaap--NatureOfOperations_zju25ic0hP72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_825_zYgnCi8ndNx9">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in February 2022 from the FDA for the Pure-Vu EVS System and has commenced commercialization of this product. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7400000 | usd | |
MOTS |
Net Cash Used In Operating Activities
NetCashUsedInOperatingActivities
|
-7300000 | usd | |
CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8500000 | usd |
CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-148700000 | usd |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_84D_eus-gaap--UseOfEstimates_zSKxpwZV8KE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zbERwkYtCat8">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | ||
CY2023Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5001276 | shares |
CY2022Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
827101 | shares |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5001276 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
827101 | shares | |
MOTS |
Rate Of Royalty Payment
RateOfRoyaltyPayment
|
0.03 | pure | |
CY2022 | MOTS |
Rate Of Royalty Payment
RateOfRoyaltyPayment
|
0.03 | pure |
CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1209000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1325000 | usd |
CY2023Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
113000 | usd |
us-gaap |
Servicing Liability At Fair Value Description Of Other Changes In Fair Value
ServicingLiabilityAtFairValueDescriptionOfOtherChangesInFairValue
|
The Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by $95 and a 2% increase in the discount rate would decrease the liability by $86. Such amounts are based on highly sensitive estimates and actual results could result in material change in future periods | ||
CY2023Q2 | MOTS |
Cost Of Revenue Impairment Of Inventory
CostOfRevenueImpairmentOfInventory
|
30000 | usd |
MOTS |
Cost Of Revenue Impairment Of Inventory
CostOfRevenueImpairmentOfInventory
|
195000 | usd | |
CY2022Q2 | MOTS |
Cost Of Revenue Impairment Of Inventory
CostOfRevenueImpairmentOfInventory
|
0 | usd |
MOTS |
Cost Of Revenue Impairment Of Inventory
CostOfRevenueImpairmentOfInventory
|
159000 | usd | |
CY2023Q2 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
553000 | usd |
CY2022Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
697000 | usd |
CY2023Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
177000 | usd |
CY2022Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
155000 | usd |
CY2023Q2 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
689000 | usd |
CY2022Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
548000 | usd |
CY2023Q2 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
596000 | usd |
CY2022Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
401000 | usd |
CY2023Q2 | us-gaap |
Inventory Net
InventoryNet
|
823000 | usd |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
999000 | usd |
CY2023Q2 | MOTS |
Inventory Current
InventoryCurrent
|
446000 | usd |
CY2022Q4 | MOTS |
Inventory Current
InventoryCurrent
|
488000 | usd |
CY2023Q2 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
377000 | usd |
CY2022Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
511000 | usd |
CY2023Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3332000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3218000 | usd |
CY2023Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2123000 | usd |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1893000 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
230000 | usd | |
CY2022Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
129000 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
253000 | usd | |
CY2023Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2000 | usd |
CY2022Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
23000 | usd |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
18000 | usd | |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
62000 | usd | |
CY2023Q2 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
39000 | usd |
CY2022Q2 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
30000 | usd |
us-gaap |
Variable Lease Cost
VariableLeaseCost
|
64000 | usd | |
us-gaap |
Variable Lease Cost
VariableLeaseCost
|
60000 | usd | |
CY2023Q2 | us-gaap |
Lease Cost
LeaseCost
|
41000 | usd |
CY2022Q2 | us-gaap |
Lease Cost
LeaseCost
|
53000 | usd |
us-gaap |
Lease Cost
LeaseCost
|
82000 | usd | |
us-gaap |
Lease Cost
LeaseCost
|
122000 | usd | |
CY2023Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
332000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
428000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
243000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
245000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
79000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
178000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
322000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
423000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y5M8D | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y9M14D | |
CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0730 | pure |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0736 | pure |
CY2023Q2 | us-gaap |
Direct Taxes And Licenses Costs
DirectTaxesAndLicensesCosts
|
60000 | usd |
CY2022Q2 | us-gaap |
Direct Taxes And Licenses Costs
DirectTaxesAndLicensesCosts
|
60000 | usd |
us-gaap |
Direct Taxes And Licenses Costs
DirectTaxesAndLicensesCosts
|
109000 | usd | |
us-gaap |
Direct Taxes And Licenses Costs
DirectTaxesAndLicensesCosts
|
107000 | usd | |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
470000 | usd | |
us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
123000 | usd | |
us-gaap |
Interest Expense
InterestExpense
|
593000 | usd | |
CY2023Q2 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
224000 | usd |
CY2023Q2 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
61000 | usd |
CY2023Q2 | us-gaap |
Interest Expense
InterestExpense
|
285000 | usd |
us-gaap |
Manufacturing Costs
ManufacturingCosts
|
38000 | usd | |
CY2023Q2 | MOTS |
License Fees
LicenseFees
|
60000 | usd |
MOTS |
License Fees
LicenseFees
|
109000 | usd | |
CY2022Q2 | MOTS |
License Fees
LicenseFees
|
60000 | usd |
MOTS |
License Fees
LicenseFees
|
107000 | usd | |
CY2023Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
49000 | usd |
CY2022Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
461000 | usd |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
271000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
982000 | usd | |
CY2023Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.0001 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
0 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
26 | shares | |
CY2023Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
525000 | shares |
CY2023Q1 | us-gaap |
Restructuring And Related Cost Description
RestructuringAndRelatedCostDescription
|
the Company commenced a strategic restructuring program aimed at capital preservation. In April 2023, the Company approved the implementation of additional cost cutting measures, including an executive reorganization and other cuts in clinical expenses, in connection with its ongoing efforts to reduce operating expenses. In addition, the non-management members of the Board agreed to defer their Board fees until a future date | |
CY2023Q2 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
416000 | usd |
us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
1423000 | usd | |
CY2023Q2 | us-gaap |
Restructuring Charges
RestructuringCharges
|
94000 | usd |
us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
1423000 | usd | |
CY2023Q2 | MOTS |
Restructuring Liabilities
RestructuringLiabilities
|
94000 | usd |